denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Are Alternative Donors Now Mainstream in Allogeneic Transplant?
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, Acute Myeloid Malignancies, Clinical Practice (Health Services and Quality), Lymphomas, Workforce, Clinical Research, Plasma Cell Disorders, Diversity, Equity, and Inclusion (DEI) , health disparities research, Chronic Myeloid Malignancies, Diseases, real-world evidence, registries, Lymphoid Malignancies, Myeloid Malignancies
Session: Are Alternative Donors Now Mainstream in Allogeneic Transplant?
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, Acute Myeloid Malignancies, Clinical Practice (Health Services and Quality), Lymphomas, Workforce, Clinical Research, Plasma Cell Disorders, Diversity, Equity, and Inclusion (DEI) , health disparities research, Chronic Myeloid Malignancies, Diseases, real-world evidence, registries, Lymphoid Malignancies, Myeloid Malignancies
Saturday, December 10, 2022, 4:00 PM-5:15 PM
Disclosures: Al Malki: NexImmune: Consultancy, Research Funding; Hasna Biopharma: Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Research Funding; Miltenyi Biotec: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; CareDx: Consultancy, Research Funding.
See more of: Are Alternative Donors Now Mainstream in Allogeneic Transplant?
See more of: Education Program
See more of: Education Program
Previous Presentation
|
Next Presentation >>